Search
Research
Molecular characterization of Der p 10: A diagnostic marker for broad sensitization in house dust mite allergyTropomyosins represent clinically relevant seafood allergens but the role of mite tropomyosin
Research
A diagnostic test for scabies: IgE specificity for a recombinant allergen of Sarcoptes scabieiScabies infestations are difficult to diagnose clinically and current serologic tests have less than 50% accuracy...
Research
CD4 allergen tetramersThe introduction of class II tetramers for identifying antigen-binding CD41 cells has lagged behind the use of class I tetramers because of difficulties...
Research
Homology modeling and monoclonal antibody binding of the der f 7 dust mite allergenThe group 7 allergens are important allergenic specificities for mite-sensitive patients and may need to be incorporated into new diagnostic and therapeutic...
Research
Structural and IgE binding analyses of recombinant Der p 2 expressed from the hosts Escherichia coli and Pichia pastorisThe house dust mite allergen Der p 2 is one of the most important indoor allergens associated with allergic disease.
Research
House dust mite allergens in asthma and allergyIgE antibodies in house dust mite (HDM) allergy follow a predictable pattern. Half are directed against two dominant allergens and the remainder largely against
Research
Barriers and Considerations for Diagnosing Rare Diseases in Indigenous PopulationsAdvances in omics and specifically genomic technologies are increasingly transforming rare disease diagnosis. However, the benefits of these advances are disproportionately experienced within and between populations, with Indigenous populations frequently experiencing diagnostic and therapeutic inequities. The International Rare Disease Research Consortium (IRDiRC) multi-stakeholder partnership has been advancing toward the vision of all people living with a rare disease receiving an accurate diagnosis, care, and available therapy within 1 year of coming to medical attention. In order to further progress toward this vision, IRDiRC has created a taskforce to explore the access barriers to diagnosis of rare genetic diseases faced by Indigenous peoples, with a view of developing recommendations to overcome them.
Research
Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human LifeNeonates have heightened susceptibility to infections. The biological mechanisms are incompletely understood but thought to be related to age-specific adaptations in immunity due to resource constraints during immune system development and growth. We present here an extended analysis of our proteomics study of peripheral blood-plasma from a study of healthy full-term newborns delivered vaginally, collected at the day of birth and on day of life (DOL) 1, 3, or 7, to cover the first week of life. The plasma proteome was characterized by LC-MS using our established 96-well plate format plasma proteomics platform.
Research
A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis CSafe, highly curative, short course, direct acting antiviral (DAA) therapies are now available to treat chronic hepatitis C. DAA therapy is freely available to all adults chronically infected with the hepatitis C virus (HCV) in Australia. If left untreated, hepatitis C may lead to progressive hepatic fibrosis, cirrhosis and hepatocellular carcinoma.
Research
Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenesThe re-emergence of scarlet fever poses a new global public health threat. The capacity of North-East Asian serotype M12 (emm12) Streptococcus pyogenes (group A Streptococcus, GAS) to cause scarlet fever has been linked epidemiologically to the presence of novel prophages